
Alex Knapp, Forbes Staff
· 1 min read
This New Partnership Aims To Use AI To Fight Cancer
Building better AI models to tackle cancer. The ever-growing launch capacity gap. Ukraine’s “flying modems.” There’s all that and more in this week’s Prototype. To get it in your inbox, sign up here.
Using AI to develop new drugs has been promising for a long time—with efforts well pre-dating the arrival of ChatGPT. But so far, it hasn’t lived up to its potential: No AI-designed drugs have yet been approved by the FDA. And while it’s true that there are a handful currently in the late stages of human trials, there are also a number that didn’t pan out as testing developed.
Noetik co-founder and CEO Ron Alfa told me this is because AI is being applied to the wrong task. “Pharma has dozens and dozens of programs in their pipelines,” he told me. “The problem is not ‘How do we make more molecules?’–the problem is, ‘How do we get things to work in patients more efficiently so we’re not spending billions of dollars on failed drugs?’”
To tackle this problem, the San Francisco-based company is building multimodal AI models that are built around the progression of cancer, providing connections between standard images of cancer cells and the genetics that underlie them. This, Alfa said, provides the software with a more comprehensive dataset, enabling it to better predict how a particular drug will impact a cancer patient. These are in turn licensed to big pharma companies like GSK for use in their drug development programs.
This week, the company announced a partnership with Memorial Sloan Kettering Cancer Center (MSK) that will help enhance those AI models with access to MSK’s datasets, which track the progression of a variety of cancers in patients and their response to various treatments.
Got questions? Comments? Story tips? Music recommendations? Email me at: theprototype@forbes.com
Original source
This story was published by Forbes: Innovation and written by Alex Knapp, Forbes Staff. SyncAI.news shows a preview; the complete article is on the publisher's site.
Read the full story on forbes.com


